Section Arrow
ATHA.NASDAQ
- Athira Pharma
Quotes are at least 15-min delayed:2024/05/16 13:22 EDT
Last
 2.549
+0.339 (+15.34%)
Day High 
2.55 
Prev. Close
2.21 
1-M High
2.33 
Volume 
212.87K 
Bid
2.54
Ask
2.55
Day Low
2.24 
Open
2.34 
1-M Low
1.895 
Market Cap 
84.70M 
Currency USD 
P/E -- 
%Yield
10-SMA 2.13 
20-SMA 2.07 
50-SMA 2.4 
52-W High 4.2984 
52-W Low 1.33 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.09/--
Enterprise Value
85.92M
Balance Sheet
Book Value Per Share
3.40
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
SCPXScorpius Holdings0.10658+0.02888+37.17%-- 
DNAGinkgo Bioworks Holdings0.8339-0.0052-0.62%-- 
JAGXJaguar Health0.2854+0.0303+11.88%-- 
NBYNovaBay Pharmaceuticals0.12308+0.01858+17.78%-- 
NVAXNovavax13.22+0.32+2.48%-- 
Quotes are at least 15-min delayed:2024/05/16 13:22 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 andATH-1019.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.